Insulin B-chain vaccine - Orban Biotech

Drug Profile

Insulin B-chain vaccine - Orban Biotech

Alternative Names: IBC-VS01

Latest Information Update: 04 Feb 2016

Price : $50

At a glance

  • Originator Orban Biotech
  • Class Antihyperglycaemics; Diabetes mellitus vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 04 Feb 2016 No recent reports on development identified - Phase-I for Type-1 diabetes mellitus in USA (IM)
  • 04 Feb 2016 No recent reports on development identified - Preclinical for Type-1 diabetes mellitus (Combination therapy) in USA (IM)
  • 05 Aug 2011 Preclinical trials in Type-1 diabetes mellitus in USA (combination therapy) (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top